50517-12-9Relevant articles and documents
NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF
-
Page/Page column 166, (2021/12/28)
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) comprises at least one covalently bound -ONO2 or -ONO moiety and at most four covalently bound -ONO2 or -ONO moieties, and wherein AR, R1, X, R3 and R4 are as defined in claim 1; and pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.
Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping
Hall, Adrian,Billinton, Andy,Brown, Susan H.,Chowdhury, Anita,Giblin, Gerard M.P.,Goldsmith, Paul,Hurst, David N.,Naylor, Alan,Patel, Sadhana,Scoccitti, Tiziana,Theobald, Pamela J.
, p. 2684 - 2690 (2008/12/21)
We describe the medicinal chemistry approach that generated a novel indole series of EP1 receptor antagonists. The SAR of this new template was evaluated and culminated in the identification of compound 12g which demonstrated in vivo efficacy i
Tryptophane and 3-indolepyruvic acid, methods of production therefor
-
, (2008/06/13)
3-indolepyruvic acid derivatives substituted on the benzene moiety show good antagonizing activity on excitatory aminoacids and on free radicals, for which reason they are therapeutic agents in cerebral and peripheral degenerative pathologies. Their metho